On Wednesday shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) closed at $69.71. Company’s sales growth for last 5 years was 112.30% and EPS growth for next 5 years is recorded as 21.80%. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) will present on April 14, 2015 at Needham & Company’s 14th Annual Healthcare Conference at the Westin Grand Central Hotel in New York City. Arthur Przybyl, President and CEO, will present at 8:40 AM ET on Tuesday, April 14, 2015.
E-House (China) Holdings Limited (ADR) (NYSE:EJ) in last trading activity increased 6.99% to close at $6.12. Company weekly performance is 12.71% while its quarterly performance stands at -25.18%. E-House (China) Holdings Limited (ADR) (NYSE:EJ) is -45.97% away from its 52 week high. E-House (China) Holdings Limited (NYSE:EJ), announced that it has entered into a definitive agreement (the “Definitive Agreement”) with Jupai Holdings Limited (“Jupai”), a leading third-party wealth management service provider in China, regarding the proposed transfer of E-House Capital, the asset management business unit of E-House focusing on the design and management of real estate or related investment projects and funds, to Jupai (the “Transaction”).
On last trading day Broadway Financial Corporation (NASDAQ:BYFC) moved down -0.01% to close at $1.35. Its volatility for the week is 2.85% while volatility for the month is 2.41%. BYFC’s sales growth for past 5 years was -11.40% and its EPS growth for past 5 years was 15.20%. Broadway Financial Corporation (NASDAQ:BYFC) monthly performance is 2.27%.
General Moly, Inc. (NYSEMKT:GMO) has 3.60% insider ownership while its institutional ownership stands at 15.80%. In last trading activity company’s stock closed at $0.51. General Moly Inc. (NYSEMKT:GMO) presented at the John Tumazos Very Independent Research Metals & Natural Resources Conference in New York, NY, on March 30, 2015.
On last trading day Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) increased 6.19% to close at $14.42. Its volatility for the week is 5.88% while volatility for the month is 5.51%. INFI’s sales growth for past 5 years was 26.60% and its EPS growth for past 5 years was 21.40%. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) monthly performance is -8.68%. Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced that it has exercised its option to buy out all future royalty obligations due to Takeda Pharmaceutical Company Limited for sales of duvelisib (IPI-145), Infinity’s dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in oncology indications. The option was purchased in July 2014 for $5.0 million from a Takeda affiliate, and the exercise fee was $52.5 million.